We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Prana Biotechnology will not proceed with supporting the initiation of the PLACQUE
study evaluating PBT1 (clioquinol) for Alzheimer's disease and has re-evaluated
any further work on the PBT1 program.
Spectrum Pharmaceuticals has announced the launch of a Phase II trial to evaluate
the safety and efficacy of SPI-153 as a treatment for patients with hormone-dependent
prostate cancer.
AEterna Zentaris has initiated a European multicenter Phase II trial to evaluate
the safety and efficacy of D-63153, a fourth generation LHRH (Luteinizing Hormone
Releasing Hormone) antagonist, in patients with hormone-dependent prostate cancer.
An independent data monitoring committee (IDMC) has recommended that Northfield
Laboratories' pivotal Phase III trial with PolyHeme continue without modification
following the third planned interim analysis of the study data.
Sepracor has announced preliminary results from its second six-month, Phase
IIIb/IV, randomized, double-blind, placebo-controlled safety and efficacy study
of Lunesta brand eszopiclone for the treatment of insomnia.
EntreMed shares climbed by more than 3 percent in premarket trading after the
company presented encouraging preclinical data for Panzem in rheumatoid arthritis.
Argos Therapeutics has announced the start of a clinical trial using a novel
personalized melanoma vaccine based on the company's proprietary technology.
Affymax has announced it has initiated a Phase II trial of its lead investigational
product Hematide, a synthetic, peptide-based erythropoiesis stimulating agent,
which is being developed to stimulate production of red blood cells for the
treatment of anemia in patients with chronic kidney disease (CKD) and cancer.
XenoPort has announced results from a Phase IIa clinical trial demonstrating
that its most advanced product candidate, known as XP13512, provided statistically
significant and clinically relevant benefits to patients with post-herpetic
neuralgia (PHN) when administered twice a day.
Gardasil, the investigational vaccine against human papillomavirus (HPV) from
Merck, has been found to significantly reduce the combined incidence of persistent
HPV 6, 11, 16, or 18 infection and related diseases, including new cervical
pre-cancers and genital warts compared to placebo in a Phase II study published
for the first time in The Lancet Oncology.